drugset / Trial / NCT03654703

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

NCT03654703 ↗

Phase 2 Unknown 100 enrolled Capital Research Institute of Pediatrics
RandomizedParallel-groupDouble-blindTreatment

Summary

No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory acute myeloid leukemia (R-AML)patients. Investigators reasoned that this group of patients if they have been treated with ablative conditioning regimens for HSCT combined with PT/Cy, under the rapid of immune reconstitution will have better outcomes.

Timeline

Start
2015-03-01
Primary completion
2018-07-01
Completion
2020-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg/kg —

Indications